INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $55,808,886 | +271.2% | 3,010,188 | +121.4% | 0.02% | +280.0% |
Q2 2023 | $15,035,749 | +320.5% | 1,359,471 | +410.6% | 0.01% | +150.0% |
Q1 2023 | $3,575,442 | -17.3% | 266,228 | -23.8% | 0.00% | 0.0% |
Q4 2022 | $4,322,054 | +54.1% | 349,398 | +73.7% | 0.00% | +100.0% |
Q3 2022 | $2,805,000 | -14.1% | 201,105 | -14.9% | 0.00% | -50.0% |
Q2 2022 | $3,265,000 | -37.6% | 236,370 | -26.5% | 0.00% | 0.0% |
Q1 2022 | $5,232,000 | +12.7% | 321,560 | +12.9% | 0.00% | 0.0% |
Q4 2021 | $4,643,000 | -22.7% | 284,942 | -29.5% | 0.00% | 0.0% |
Q3 2021 | $6,003,000 | -57.0% | 404,279 | -42.2% | 0.00% | -60.0% |
Q2 2021 | $13,971,000 | -15.5% | 699,572 | -2.3% | 0.01% | 0.0% |
Q1 2021 | $16,528,000 | +12.2% | 716,120 | +20.1% | 0.01% | 0.0% |
Q4 2020 | $14,725,000 | -40.6% | 596,159 | -0.3% | 0.01% | -44.4% |
Q3 2020 | $24,785,000 | -18.5% | 597,800 | -5.8% | 0.01% | -30.8% |
Q2 2020 | $30,404,000 | -24.1% | 634,594 | -0.3% | 0.01% | -31.6% |
Q1 2020 | $40,074,000 | -50.3% | 636,512 | -2.2% | 0.02% | -32.1% |
Q4 2019 | $80,676,000 | +59.0% | 651,022 | -14.8% | 0.03% | +40.0% |
Q3 2019 | $50,728,000 | -4.4% | 764,445 | +14.6% | 0.02% | -4.8% |
Q2 2019 | $53,070,000 | -24.9% | 666,940 | +5.5% | 0.02% | -27.6% |
Q1 2019 | $70,683,000 | +7.4% | 631,893 | -3.2% | 0.03% | 0.0% |
Q4 2018 | $65,793,000 | -20.9% | 652,768 | -0.8% | 0.03% | -12.1% |
Q3 2018 | $83,148,000 | +54.3% | 658,021 | +2.5% | 0.03% | +43.5% |
Q2 2018 | $53,891,000 | +11.5% | 642,245 | -18.2% | 0.02% | +15.0% |
Q1 2018 | $48,319,000 | +7.5% | 785,420 | +2.0% | 0.02% | +5.3% |
Q4 2017 | $44,968,000 | +1.7% | 769,745 | +1.0% | 0.02% | -9.5% |
Q3 2017 | $44,233,000 | -49.5% | 762,115 | +5.3% | 0.02% | -53.3% |
Q2 2017 | $87,641,000 | +13.4% | 723,894 | +6.0% | 0.04% | +7.1% |
Q1 2017 | $77,271,000 | -0.4% | 683,214 | -4.3% | 0.04% | -2.3% |
Q4 2016 | $77,572,000 | -29.8% | 713,967 | +6.3% | 0.04% | -34.8% |
Q3 2016 | $110,557,000 | +42.2% | 671,713 | +23.3% | 0.07% | +34.7% |
Q2 2016 | $77,747,000 | +5816.8% | 544,903 | +5229.1% | 0.05% | +4800.0% |
Q1 2016 | $1,314,000 | -66.0% | 10,225 | -60.5% | 0.00% | -50.0% |
Q4 2015 | $3,869,000 | +74.7% | 25,900 | +94.0% | 0.00% | +100.0% |
Q3 2015 | $2,215,000 | -52.1% | 13,350 | -30.3% | 0.00% | -66.7% |
Q2 2015 | $4,623,000 | -0.7% | 19,154 | +16.1% | 0.00% | 0.0% |
Q1 2015 | $4,654,000 | +224.8% | 16,502 | +79.8% | 0.00% | +200.0% |
Q4 2014 | $1,433,000 | – | 9,178 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |